Open AccessPristimerin Protects Against OVX-Mediated Bone Loss by Attenuating Osteoclast Formation and Activity via Inhibition of RANKL-Mediated Activation of NF-κB and ERK Signaling Pathways
Author(s) -
Xuedong Li,
Xiaofeng Lin,
Zuoxing Wu,
Yuangang Su,
Jiamin Liang,
Runfeng Chen,
Xue Yang,
Lei Hou,
Jinmin Zhao,
Qian Liu,
Feng Xu
Publication year - 2021
Publication title -
drug design, development and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.964
H-Index - 64
ISSN - 1177-8881
DOI - 10.2147/dddt.s283694
Subject(s) - osteoclast , mapk/erk pathway , rankl , bone resorption , in vivo , chemistry , cancer research , osteoporosis , nf κb , signal transduction , bone remodeling , microbiology and biotechnology , osteoblast , pharmacology , in vitro , medicine , activator (genetics) , biology , receptor , biochemistry